Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants
Purpose An evaluation was made of the effectiveness in changing prescribing behavior of ‘Dear Health Professional (DHP)’ letters mailed by the manufacturer to physicians and other health professionals advising them of safety information on co‐prescribing of tramadol and antidepressants. Methods A re...
Gespeichert in:
| Veröffentlicht in: | Pharmacoepidemiology and drug safety 2005-03, Vol.14 (3), p.149-154 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 154 |
|---|---|
| container_issue | 3 |
| container_start_page | 149 |
| container_title | Pharmacoepidemiology and drug safety |
| container_volume | 14 |
| creator | Shatin, Deborah Gardner, Jacqueline S. Stergachis, Andy Blough, David Graham, David |
| description | Purpose
An evaluation was made of the effectiveness in changing prescribing behavior of ‘Dear Health Professional (DHP)’ letters mailed by the manufacturer to physicians and other health professionals advising them of safety information on co‐prescribing of tramadol and antidepressants.
Methods
A retrospective cohort analysis of prescription claims of all plan members from 12 UnitedHealth Group‐affiliated health plans who received a first prescription for tramadol between 1 April 1995 and 31 December 1996. The prevalence of co‐prescribing of antidepressants and tramadol relative to the date of the ‘DHP’ communication was determined.
Results
9218 plan members received an initial prescription for tramadol within the observation period. Prior to the date of the ‘DHP’ communication 1061/4774 (22.2%) members received a prescription for an antidepressant within 30 days of their first prescription for tramadol. Following the date of the communication 844/4444 (19.0%) of members received an antidepressant within 30 days of their first prescription for tramadol. An overall decreasing linear trend in antidepressant co‐prescribing was evident over the observation period, but there was no statistically significant acceleration in the decrease following this communication.
Conclusions
The mailed ‘DHP’ advisory letter did not affect the rate of co‐prescribing of tramadol with antidepressants. Copyright © 2004 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/pds.961 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pds_961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_J1FGS1ZC_8</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3781-cfbffdb3edbd0982a35364dbc191e8e02583a6bc148f21203ab1a5e26aab693d3</originalsourceid><addsrcrecordid>eNp1kE1PAyEQhonRWK3Gf2C4eTBbYVlYOJpqa02jJtWYeJDAwupq9yOAqf330myjJw8Thpln3sMDwAlGI4xQetEZPxIM74ADjIRIMKX57qanJOGUiQE49P4DobgT2T4YYEo4y3F2AF5ndaeKANsS1qpaWgNXyjVV8wZDCztnfeEqbZ2HbQPDu4VFm2ynXajiLN4Fp2pl2iVUjYkVKmM3iI-tPwJ7pVp6e7x9h-Bpcv04vknm99PZ-HKeFCTnOClKXZZGE2u0QYKnilDCMqMLLLDlFqWUE8XiN-NlilNElMaK2pQppZkghgzBWZ9buNZ7Z0vZuapWbi0xkhtDMhqS0VAkT3uy-9K1NX_cVkkEzntgFXWs_8uRD1eLPi7p6coH-_1LK_cpWU5yKp_vpvIWT6YL_DKWnPwAaE-AQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Shatin, Deborah ; Gardner, Jacqueline S. ; Stergachis, Andy ; Blough, David ; Graham, David</creator><creatorcontrib>Shatin, Deborah ; Gardner, Jacqueline S. ; Stergachis, Andy ; Blough, David ; Graham, David</creatorcontrib><description>Purpose
An evaluation was made of the effectiveness in changing prescribing behavior of ‘Dear Health Professional (DHP)’ letters mailed by the manufacturer to physicians and other health professionals advising them of safety information on co‐prescribing of tramadol and antidepressants.
Methods
A retrospective cohort analysis of prescription claims of all plan members from 12 UnitedHealth Group‐affiliated health plans who received a first prescription for tramadol between 1 April 1995 and 31 December 1996. The prevalence of co‐prescribing of antidepressants and tramadol relative to the date of the ‘DHP’ communication was determined.
Results
9218 plan members received an initial prescription for tramadol within the observation period. Prior to the date of the ‘DHP’ communication 1061/4774 (22.2%) members received a prescription for an antidepressant within 30 days of their first prescription for tramadol. Following the date of the communication 844/4444 (19.0%) of members received an antidepressant within 30 days of their first prescription for tramadol. An overall decreasing linear trend in antidepressant co‐prescribing was evident over the observation period, but there was no statistically significant acceleration in the decrease following this communication.
Conclusions
The mailed ‘DHP’ advisory letter did not affect the rate of co‐prescribing of tramadol with antidepressants. Copyright © 2004 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.961</identifier><identifier>PMID: 15386714</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adult ; Analgesics, Opioid - adverse effects ; Analgesics, Opioid - therapeutic use ; antidepressants ; Antidepressive Agents - adverse effects ; Antidepressive Agents - therapeutic use ; codispensing ; Cohort Studies ; contraindicated ; Dear Doctor ; Drug Industry - methods ; Drug Industry - statistics & numerical data ; Drug Prescriptions - statistics & numerical data ; Drug Therapy, Combination ; Drug Utilization Review - methods ; Drug Utilization Review - statistics & numerical data ; drugs/adverse effects ; Humans ; Information Dissemination - methods ; Insurance, Pharmaceutical Services - statistics & numerical data ; postmarketing ; Practice Patterns, Physicians ; product surveillance ; Retrospective Studies ; risk communication ; Time Factors ; tramadol ; Tramadol - adverse effects ; Tramadol - therapeutic use</subject><ispartof>Pharmacoepidemiology and drug safety, 2005-03, Vol.14 (3), p.149-154</ispartof><rights>Copyright © 2004 John Wiley & Sons, Ltd.</rights><rights>Copyright 2004 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3781-cfbffdb3edbd0982a35364dbc191e8e02583a6bc148f21203ab1a5e26aab693d3</citedby><cites>FETCH-LOGICAL-c3781-cfbffdb3edbd0982a35364dbc191e8e02583a6bc148f21203ab1a5e26aab693d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.961$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.961$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15386714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shatin, Deborah</creatorcontrib><creatorcontrib>Gardner, Jacqueline S.</creatorcontrib><creatorcontrib>Stergachis, Andy</creatorcontrib><creatorcontrib>Blough, David</creatorcontrib><creatorcontrib>Graham, David</creatorcontrib><title>Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidem. Drug Safe</addtitle><description>Purpose
An evaluation was made of the effectiveness in changing prescribing behavior of ‘Dear Health Professional (DHP)’ letters mailed by the manufacturer to physicians and other health professionals advising them of safety information on co‐prescribing of tramadol and antidepressants.
Methods
A retrospective cohort analysis of prescription claims of all plan members from 12 UnitedHealth Group‐affiliated health plans who received a first prescription for tramadol between 1 April 1995 and 31 December 1996. The prevalence of co‐prescribing of antidepressants and tramadol relative to the date of the ‘DHP’ communication was determined.
Results
9218 plan members received an initial prescription for tramadol within the observation period. Prior to the date of the ‘DHP’ communication 1061/4774 (22.2%) members received a prescription for an antidepressant within 30 days of their first prescription for tramadol. Following the date of the communication 844/4444 (19.0%) of members received an antidepressant within 30 days of their first prescription for tramadol. An overall decreasing linear trend in antidepressant co‐prescribing was evident over the observation period, but there was no statistically significant acceleration in the decrease following this communication.
Conclusions
The mailed ‘DHP’ advisory letter did not affect the rate of co‐prescribing of tramadol with antidepressants. Copyright © 2004 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Analgesics, Opioid - adverse effects</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>antidepressants</subject><subject>Antidepressive Agents - adverse effects</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>codispensing</subject><subject>Cohort Studies</subject><subject>contraindicated</subject><subject>Dear Doctor</subject><subject>Drug Industry - methods</subject><subject>Drug Industry - statistics & numerical data</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Drug Therapy, Combination</subject><subject>Drug Utilization Review - methods</subject><subject>Drug Utilization Review - statistics & numerical data</subject><subject>drugs/adverse effects</subject><subject>Humans</subject><subject>Information Dissemination - methods</subject><subject>Insurance, Pharmaceutical Services - statistics & numerical data</subject><subject>postmarketing</subject><subject>Practice Patterns, Physicians</subject><subject>product surveillance</subject><subject>Retrospective Studies</subject><subject>risk communication</subject><subject>Time Factors</subject><subject>tramadol</subject><subject>Tramadol - adverse effects</subject><subject>Tramadol - therapeutic use</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1PAyEQhonRWK3Gf2C4eTBbYVlYOJpqa02jJtWYeJDAwupq9yOAqf330myjJw8Thpln3sMDwAlGI4xQetEZPxIM74ADjIRIMKX57qanJOGUiQE49P4DobgT2T4YYEo4y3F2AF5ndaeKANsS1qpaWgNXyjVV8wZDCztnfeEqbZ2HbQPDu4VFm2ynXajiLN4Fp2pl2iVUjYkVKmM3iI-tPwJ7pVp6e7x9h-Bpcv04vknm99PZ-HKeFCTnOClKXZZGE2u0QYKnilDCMqMLLLDlFqWUE8XiN-NlilNElMaK2pQppZkghgzBWZ9buNZ7Z0vZuapWbi0xkhtDMhqS0VAkT3uy-9K1NX_cVkkEzntgFXWs_8uRD1eLPi7p6coH-_1LK_cpWU5yKp_vpvIWT6YL_DKWnPwAaE-AQQ</recordid><startdate>200503</startdate><enddate>200503</enddate><creator>Shatin, Deborah</creator><creator>Gardner, Jacqueline S.</creator><creator>Stergachis, Andy</creator><creator>Blough, David</creator><creator>Graham, David</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200503</creationdate><title>Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants</title><author>Shatin, Deborah ; Gardner, Jacqueline S. ; Stergachis, Andy ; Blough, David ; Graham, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3781-cfbffdb3edbd0982a35364dbc191e8e02583a6bc148f21203ab1a5e26aab693d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Analgesics, Opioid - adverse effects</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>antidepressants</topic><topic>Antidepressive Agents - adverse effects</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>codispensing</topic><topic>Cohort Studies</topic><topic>contraindicated</topic><topic>Dear Doctor</topic><topic>Drug Industry - methods</topic><topic>Drug Industry - statistics & numerical data</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Drug Therapy, Combination</topic><topic>Drug Utilization Review - methods</topic><topic>Drug Utilization Review - statistics & numerical data</topic><topic>drugs/adverse effects</topic><topic>Humans</topic><topic>Information Dissemination - methods</topic><topic>Insurance, Pharmaceutical Services - statistics & numerical data</topic><topic>postmarketing</topic><topic>Practice Patterns, Physicians</topic><topic>product surveillance</topic><topic>Retrospective Studies</topic><topic>risk communication</topic><topic>Time Factors</topic><topic>tramadol</topic><topic>Tramadol - adverse effects</topic><topic>Tramadol - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shatin, Deborah</creatorcontrib><creatorcontrib>Gardner, Jacqueline S.</creatorcontrib><creatorcontrib>Stergachis, Andy</creatorcontrib><creatorcontrib>Blough, David</creatorcontrib><creatorcontrib>Graham, David</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shatin, Deborah</au><au>Gardner, Jacqueline S.</au><au>Stergachis, Andy</au><au>Blough, David</au><au>Graham, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidem. Drug Safe</addtitle><date>2005-03</date><risdate>2005</risdate><volume>14</volume><issue>3</issue><spage>149</spage><epage>154</epage><pages>149-154</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
An evaluation was made of the effectiveness in changing prescribing behavior of ‘Dear Health Professional (DHP)’ letters mailed by the manufacturer to physicians and other health professionals advising them of safety information on co‐prescribing of tramadol and antidepressants.
Methods
A retrospective cohort analysis of prescription claims of all plan members from 12 UnitedHealth Group‐affiliated health plans who received a first prescription for tramadol between 1 April 1995 and 31 December 1996. The prevalence of co‐prescribing of antidepressants and tramadol relative to the date of the ‘DHP’ communication was determined.
Results
9218 plan members received an initial prescription for tramadol within the observation period. Prior to the date of the ‘DHP’ communication 1061/4774 (22.2%) members received a prescription for an antidepressant within 30 days of their first prescription for tramadol. Following the date of the communication 844/4444 (19.0%) of members received an antidepressant within 30 days of their first prescription for tramadol. An overall decreasing linear trend in antidepressant co‐prescribing was evident over the observation period, but there was no statistically significant acceleration in the decrease following this communication.
Conclusions
The mailed ‘DHP’ advisory letter did not affect the rate of co‐prescribing of tramadol with antidepressants. Copyright © 2004 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>15386714</pmid><doi>10.1002/pds.961</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-8569 |
| ispartof | Pharmacoepidemiology and drug safety, 2005-03, Vol.14 (3), p.149-154 |
| issn | 1053-8569 1099-1557 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_pds_961 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Analgesics, Opioid - adverse effects Analgesics, Opioid - therapeutic use antidepressants Antidepressive Agents - adverse effects Antidepressive Agents - therapeutic use codispensing Cohort Studies contraindicated Dear Doctor Drug Industry - methods Drug Industry - statistics & numerical data Drug Prescriptions - statistics & numerical data Drug Therapy, Combination Drug Utilization Review - methods Drug Utilization Review - statistics & numerical data drugs/adverse effects Humans Information Dissemination - methods Insurance, Pharmaceutical Services - statistics & numerical data postmarketing Practice Patterns, Physicians product surveillance Retrospective Studies risk communication Time Factors tramadol Tramadol - adverse effects Tramadol - therapeutic use |
| title | Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A03%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20mailed%20warning%20to%20prescribers%20on%20the%20co-prescription%20of%20tramadol%20and%20antidepressants&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Shatin,%20Deborah&rft.date=2005-03&rft.volume=14&rft.issue=3&rft.spage=149&rft.epage=154&rft.pages=149-154&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.961&rft_dat=%3Cistex_cross%3Eark_67375_WNG_J1FGS1ZC_8%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15386714&rfr_iscdi=true |